Currently Viewing:
Evidence-Based Diabetes Management March/April
Currently Reading
The Controversial Question of Metabolic Syndrome
Managing Benefits for Diabetes: Changing Payer Strategies for Changing Times
Albert Tzeel, MD, MHSA, FACPE
Examining Models of Care and Reimbursement, Including Patient Management Fees, ACOs, and PCMHs: A Panel Discussion
Is There a Business Case for Diabetes Disease Management?
Stanton R. Mehr
Real-World Examples of Patient-Centered Healthcare
Targeting Insulin Resistance: The Ongoing Paradigm Shift in Diabetes Prevention
Tara Dall, MD; Dawn Thiselton, PhD; and Stephen Varvel, PhD
Can Financial Incentives Improve Self-Management Behaviors?
Kim Farina, PhD
Reexamining the Roles of Diabetes Educators
Kim Farina, PhD
Diabetes and the Patient-Centered Medical Home
Teresa L. Pearson, MS, RN, CDE
Measuring the Value of Better Diabetes Management
Darius N. Lakdawalla, PhD; Michael R. Eber, BSE; Felicia M. Forma, BSc; Jeffrey Sullivan, MS; Pierre-Carl Michaud, PhD; Lily A. Bradley, MBA; and Dana P. Goldman, PhD

The Controversial Question of Metabolic Syndrome

The high prevalence of diabetes and cardiovascular disease (CVD) has tasked the medical community to not only treat but to better identify people at risk for these diseases. Risk factors for diabetes had been identified more than 90 years ago, and the term metabolic syndrome emerged in the late 1970s.1,2 In the late 1980s, a potential link had been identified—insulin resistance, which itself has been strongly associated with obesity.3 On the other hand, some believe that insulin resistance contributes to the development of the risk  actors but is not the underlying cause.4 Identifying a cluster of predictive risk factors would enable healthcare providers to identify and  treat patients with metabolic syndrome, thus reducing the risk for a progression to diabetes, CVD, or both.

The Controversy: What Is Metabolic Syndrome, and Is It a Treatable Disorder?

Metabolic syndrome (sometimes referred to as “syndrome X” or “insulin-resistance syndrome”) is defined as a grouping of several related risk factors,4 including:

• Abdominal fat

• Dyslipidemia

• Hyperglycemia

• Hypertension

Merriam-Webster defines the term syndrome as “a group of signs and symptoms that occur together and characterize a particular  abnormality.”5 What is truly more important to the final objective of preventing diabetes and CVD—identification of the underlying mechanism(s) for the syndrome, or identification of the risk factors that occur together and usually lead to diabetes and CVD?

This question defines the debate within the healthcare community: Is metabolic syndrome a cluster of risk factors or a syndrome? Proponents for  characterizing metabolic syndrome as a syndrome believe that the evidence linking the risk factors with the development of diabetes and CVD supports the view that it is a treatable entity. Detractors believe that metabolic syndrome is really just a clustering of risk factors, without any known underlying mechanism  that associates the maladies. Confounding the discussion is whether metabolic syndrome is a pre-morbid condition—whether metabolic syndrome can only  be recognized before a patient is given a diagnosis of diabetes or CVD, thus excluding the population with these highly prevalent chronic conditions. On the other hand, an actual diagnosis of diabetes or CVD does not affect the underlying mechanism (eg, insulin resistance or some other factor still exists).

Regardless of whether  professional organizations are supporters or skeptical of metabolic syndrome, the medical community as a whole believes that additional research is needed to better understand its etiology.

In 2005, the American Diabetes Association and the European Association for the Study of Diabetes published a statement underscoring their concerns regarding metabolic syndrome.6 Their concerns included the value of including diabetes in the definition, whether the criteria have accurate thresholds and are completely explanatory, and the omission of other cardiovascular disease risk factors. They worried that if the cardiovascular risk for metabolic  syndrome is the same as the sum of the individual risk factors, treatment of the syndrome would be the same as the treatment for each of the respective risk  factors. Furthermore, these professional societies were not convinced that insulin resistance is the unifying mechanism and whether there is overall value in  diagnosing the syndrome.

Yet, 2 American professional organizations and several international societies generally agree on the risk factors that should be included in the definition of  metabolic syndrome. Until this time, there were several different criteria discussed for metabolic syndrome, most notably from the World Health Organization, the National Cholesterol Education Program Adult Treatment Panel III, the International Diabetes Foundation, and the American Heart Association/National Heart, Lung, and Blood Institute. These organizations agreed on the risk factors that should be included in a definition of metabolic syndrome; however, they differed on the definition of the components and the number of risk factors that needed to be present to constitute the diagnosis. Members from these  organizations came together in 2009 to meld together consistent criteria for metabolic syndrome.4 Most disagreement involved whether body mass index or  waist circumference should be used as the indicator for central obesity. They concluded that waist circumference was a useful screening tool and should  correlate with specific country or population demographics, and that further research was required.

This coalition of professional societies did agree that having 3 of the abnormal findings from the cluster of 5 maladies would constitute a diagnosis of  metabolic syndrome (Table 1). They also agreed that people with any of the identified risk factors usually also present with a prothrombotic and proinflammatory state.

Obesity and physical inactivity have been found to be important contributors to metabolic syndrome.7 Other contributing factors include genetic and racial composition, aging, and the presence of other endocrine disorders. Patients with metabolic syndrome are usually susiceptible to additional problems as well, some that may be associated with its individual component risk factors:

• Fatty liver

• Cholesterol gallstones

• Obstructive sleep apnea

• Gout

• Depression

• Musculoskeletal disease

• Polycystic ovarian syndrome8

The Prevalence of Metabolic Syndrome

Assuming one accepts the definition of metabolic syndrome, it is unsurprising that its prevalence has increased over  time, perhaps reflecting the obesity  epidemic and predictions of greater incidence of diabetes.9 An analysis of the 2003 to 2006 National Health and Nutrition Examination Survey revealed  that, based on a waist circumference threshold of ≥102 cm for men and ≥88 cm for  women, the age-adjusted prevalence of metabolic syndrome in American adults was 34.3% (36.1% for men; 32.4% for women). This percentage increased to 38.5% for all adults when racial- or ethnic-specific criteria were used (41.9% for men; 35.0% for women). The prevalence increases with age, peaking in the 60- to 69-years group, which parallels a correlation with weight gain  with increasing age. Caucasian and Mexican-American men had a higher prevalence of metabolic syndrome than African American men, whereas the  prevalence for women was lower among Caucasian women than for African American or Mexican American women.10

Among the risk factors, abdominal obesity is observed in the majority (53.6% total [45.8% men; 61.2% women]) of the population with metabolic syndrome. The other risk factor components in the total population are, in descending order of prevalence, hyperglycemia, high triglyceride levels, elevated blood  pressure, and low concentrations of high-density lipoprotein cholesterol.

Although each of the components of metabolic syndrome increases the risk for CVD, the combination of the risk factors appears to increase it substantially. The presence of metabolic syndrome is associated with a 2-fold increased risk for CVD (and a 5-fold greater risk for the development of type 2 diabetes).8  Traditional risk algorithms for CVD, such as the Framingham Risk Score, may be more accurate in risk prediction.11

The Cost Implications of Metabolic Disease for Payers

Unsurprisingly, patients diagnosed with metabolic disease can be expected to utilize more health resources than those individuals without it. A study of  patients in 3 health plans confirmed this statement—members meeting at least 3 criteria for metabolic syndrome had 60% higher annual costs compared with patients without metabolic syndrome ($5732 vs $3581, respectively), and these costs increased incrementally by 24% when they met 4 or more risk  factors.12 When patients progressed to a diagnosis of diabetes, the healthcare costs were higher in patients with diabetes and metabolic syndrome than in  those patients with diabetes without metabolic syndrome ($7896 vs $6038, respectively). Patients with diabetes do not necessarily meet all of the criteria  required to be considered to have metabolic syndrome.12

Similar results were seen in a health plan that assessed the direct medical costs associated with patients who were overweight, obese, or met risk criteria for  metabolic syndrome using a cost model.13 Comparing patients who were overweight or obese with those who were not, direct costs were $4563 versus $4015, respectively. The highest annual costs (>$5000) were in the patients with risk factors meeting the requirements of metabolic syndrome. This cost was  $2061 higher than in those without the risk factors for metabolic syndrome.13 Both of the above studies support the hypothesis that there are increased costs associated with patients meeting the risk factor criteria for metabolic syndrome.

However, another study of health plan members concluded that the higher costs were associated with the individual risk factors rather than with a clustering of the risk factors. In this analysis, 5 years of health data were evaluated for adults with metabolic syndrome risk factors  and their impact on direct medical costs. They compared total annualized direct costs for all possible combinations of the metabolic syndrome risk components.Every risk factor except for impaired fasting glucose led to increased annual medical costs; however, the higher costs were independent of the other risk factors. The presence of each of the risk  factors was associated with higher future medical costs, which were mostly attributable to the development of diabetes or the need for hospitalization due to  cardiovascular disease.14

Current Approaches to Managing Metabolic Syndrome

Currently, there is no 1 specific treatment for treating patients meeting thecriteria for metabolic syndrome. Rather, lifestyle modification and weight  reduction, along with drug therapy for the respective risk factors (eg, hypertension, dyslipidemia, hyperglycemia, and weight reduction) are employed.  Pharmaceutical companies have found it challenging to develop medications, as they would need to address multiple aspects of metabolic syndrome in  order to be approved for the indication.15 As a result, clinicians utilize available tools to address these risk factors (and usually, on an individual basis).

From  the clinical and public health standpoint, however, the need for better tools to prevent and manage metabolic syndrome is urgent (Table 2).8 Until an  underlying mechanism is positively identified (or insulin resistance is finally recognized as the “smoking gun”), medications will be utilized that address the  respective components of metabolic syndrome.

Patient Management and Metabolic Syndrome

The most important benefit of using the term metabolic syndrome appears to be that it focuses attention on an important clustering of health problems. Each of the criteria, as well as the clustering of the criteria, increase the risk for future disease. Lifestyle modifications can address each of the criteria for metabolic syndrome; however, each component requires separate, focused treatment.

Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up

Sign In

Not a member? Sign up now!